Key result
APEX1 drives cardiovascular pathophysiology via redox and endonuclease activities, serving as potential therapeutic target.
Answers are grounded in this paper and cite their sources.
APEX1 is a multifaceted regulatory factor in cardiovascular health and a potential therapeutic target for cardiovascular diseases.
Apurinic/apyrimidinic endonuclease 1 (APEX1) serves as a potent regulatory factor in innate immunity, exhibiting both redox and endonuclease activities. Its redox function enables the regulation of transcription factors such as NF-κB or STAT3, whereas its endonuclease activity recognizes apurinic/apyrimidinic (AP) sites in damaged DNA lesions during base excision repair (BER) and double-stranded DNA repair, thereby I confirm.anti-inflammatory, antioxidative stress and antiapoptotic effects. APEX1 is expressed in a variety of cell types that constitute the cardiovascular system, including cardiomyocytes, endothelial cells, smooth muscle cells, and immune cells. Emerging genetic and experimental evidence points towards the functional roles of APEX1 in the pathophysiology of cardiovascular diseases, including neointimal formation and atherosclerosis. This review aims to present comprehensive coverage of the up-to-date literature concerning the molecular and cellular functions of APEX1, with a particular focus on how APEX1 contributes to the (dys)functions of different cell types during the pathogenesis of cardiovascular diseases. Furthermore, we underscore the potential of APEX1 as a therapeutic target for the treatment of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2025) conducted a review in Cardiovascular diseases. APEX1 (Apurinic/Apyrimidinic Endonuclease 1) was evaluated. APEX1 contributes to the pathophysiology of cardiovascular diseases through its redox and endonuclease activities, highlighting its potential as a therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: